Search results
A Zinc Deficiency Could be the Cause of Your Hair Loss — MDs Share How To Reverse It
Woman's World via Yahoo News· 1 day agoRisk factors include poor diet as well as common inflammatory gut conditions, such as IBS, Crohn’s ...
Unhealthy Nails? Kidney Disease Might Be Why—Experts Share Symptoms & Solutions
Fort Worth Star-Telegram· 6 days agoWhen it comes to kidney disease, nails can surprisingly offer critical clues that something is awry. Here’s what you need to know about the link between kidney disease ...
Primary Sjögren Disease Promotes Premature Atherogenesis
Medscape· 5 days agoPatients with primary Sjögren disease with organ involvement were at a high risk for subclinical...
Holistic Health: A Guide to Better Health and Well-Being
Health via Yahoo News· 5 days agoHow To Find a Holistic Health Practitioner Many different providers consider themselves holistic...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI...
Benzinga· 5 days agoREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 6 days agoJasper is a clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) as a therapeutic for chronic mast and stem cell diseases
Personalized Microbiome-Based Diet Shows Promise for IBS
Medscape· 5 days agoNew research highlighted the potential of a personalized microbiome-based diet, created using the...
Binge-Eating Disorder May Linger for Years
Medscape· 21 hours agoBinge-eating disorder (BED) often improves with time, but full remission can take many years and relapse is common, new research suggested. "The big...
Halia Therapeutics to Participate at BIO International Convention and The European Hematology...
The Herald Journal· 7 days agoPreliminary safety, efficacy, and biomarker data from the ongoing Phase II trial evaluating HT-6184 in MDS patients will be presented at the EHA 2024 Hybrid Congress.
ComboMATCH Precision Medicine Cancer Trials
National Cancer Institute· 9 hours agoComboMATCH (Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice) is a group of precision medicine cancer clinical trials,...